Abstract
Current interest in personalized medicine, particularly cell therapy, requires the concurrent development of new noninvasive monitoring techniques for their optimization. Imaging, particularly using MRI, has grown to be a key player in this field. Cell tracking has been carried out clinically using MRI with iron oxide contrast agents in about a dozen clinical trials. However, the use of 19F as an alternative nucleus has several potential advantages, and was recently introduced in the clinic. In this chapter, we describe the advantages of 19F MRI for cell tracking, its challenges, and some potential solutions, including the various types of fluorine labels, labeling procedures, and imaging protocols.
Access provided by CONRICYT-eBooks. Download chapter PDF
Similar content being viewed by others
Keywords
- 19F magnetic resonance imaging
- 19F MRI
- Fluorine
- Perfluorocarbons
- Nanoparticles
- Cell tracking
- Cell labeling
- Contrast agent
1 Introduction
The imaging of cellular therapeutics plays a significant and vital role in the development, optimization, and personalization of such therapy, as it can provide essential information on cell localization, number, and functionality (Fig. 1a) , thus allowing dosage and delivery optimization, among others. Magnetic resonance imaging (MRI) is an anatomic and functional imaging technique which excels at soft-tissue imaging, without limitations on penetration depth. MRI is one of the commonly used imaging modalities due to its excellent safety, noninvasive nature, high resolution, lack of ionizing radiation, and intrinsic anatomic contrast. Standard (i.e. most commonly used) MRI focuses on the detection of differences in relaxation rates of the protons (1H) in mobile water molecules in various tissues. However, it is normally not possible to distinguish specific therapeutic cells from their surrounding cellular milieu without the use of a specific label for the relevant cells. There have been several approaches to develop contrast agents (CAs) to improve contrast, e.g., gadolinium or superparamagnetic iron oxide (SPIO) . However, metal CAs can be toxic, may not allow proper cell quantification, and often require “before” and “after” images to detect changes in contrast. Only SPIO-based agents have been used in the clinic for cell tracking [1] and these agents are no longer commercially available.
In the last decade, “hot-spot” imaging has gained a lot of attention. Hot-spot imaging is hetero-nuclear MRI using 13C, 23Na, 31P, or 19F in addition to 1H, which enables direct detection rather than indirect, as is the case for CAs (Fig. 1b). Out of these four elements, 19F has been the main focus as it is essentially absent in biological tissues; thus there is no endogenous background signal, which makes it more attractive for hot-spot imaging [2]. One clear example of the advantage of the lack of background signal is a recent paper using 19F MRI to track inflammatory macrophages and monocytes in a murine model of multiple sclerosis [3]. Here the inflammatory cells were found not only in the diseased spinal cord, as expected, but also in neighboring bone marrow tissue. This ability to locate 19F signal even in unexpected locations without comparison to a “before” image, given a sufficient signal-to-noise ratio, is one of the key advantages of the technique.
19F MRI has been applied as a powerful imaging tool for diverse applications , such as cell tracking [4], drug metabolism, plaque detection, and monitoring inflammation. Cell tracking using 19F MRI has been applied to various cell types, such as dendritic cells (DCs), T cells, stem cells, and macrophages [5]. In order to distinguish relevant cells from the background, they need to be labeled with fluorinated labels, described in the following section.
2 Fluorocarbons
2.1 General Properties of Fluorine
Using fluorine in MRI has several advantages as 19F is a spin ½ nucleus, which means that it has an odd number of protons and neutrons and spherical charge distribution, and a gyromagnetic ratio close to the proton. Thus, for a given magnetic field value, the spin processes at almost the same frequency, permitting the use of a conventional proton spectrometer to detect fluorine [6]. Fluorine has 100 % natural abundance and an extremely broad chemical shift and is not naturally present in biological tissues and therefore has no biological background signal; the traces of fluorine in bone and teeth exhibit a very short spin-spin relaxation time (T2) and are not visible to conventional MRI methods [2]. In all, fluorine MRI gives a very high contrast-to-noise ratio and specificity, in a situation where a fluorinated element is introduced as a contrast agent . Such agent requires a very high density of 19F nuclei on the molecule in addition to a high tissue concentration in order to produce an image quality such as the one of 1H MRI. However, it is important to realize that the administered levels of 19F will still be many orders of magnitude lower than the amount of 1H present in biological tissues, and thus, despite all its advantages in terms of imaging properties, the low concentrations of 19F frequently result in images that hover at the detection limit with low signal-to-noise ratios (SNRs). Finally, some fluorocarbons show a T1 sensitivity to oxygen tension, which may allow its use as an in vivo sensor [2]; alternatively, this T1 variability can be a nuisance, hindering accurate quantification.
2.2 Fluorinated Compounds/Molecules
An example of fluorinated compounds includes fluorinated peptides, polymers, and also fluorinated small molecules, such as sugars; however these result in much lower cell loading and, as a result, a lower detection sensitivity. Small fluorinated molecules have lower 19F content than larger fluorocarbons, such as perfluorocarbons (PFCs); however their advantage is that they can be used to study cell functionality [5]. Despite this benefit, the insufficient sensitivity of the small molecules makes them less attractive for in vivo use. Recent developments in small fluorinated molecules include fluorinated albumin [7] and self-assembling nanoparticles sensitive to their environment [8], although neither of these have been applied to cell tracking . Some examples are listed in Table 1.
There have been limited studies using fluorinated drugs (see Table 1). The limit here is the high reactivity and electronegativity of fluorine, which when incorporated into a drug can significantly alter drug chemistry and subsequent metabolism. Chemical shift artifacts can also be an issue. For all these reasons, such small molecules are seldom used for cell tracking.
2.3 Perfluorocarbons
Perfluorocarbons (PFCs) are synthetic molecules mainly composed of carbon and fluorine atoms (see Table 2 for a summary of their physical properties). Depending on their chemical structure and molecular weight, PFCs exist in a gaseous, liquid, or even solid form. The compounds are extremely stable, generally have low vapor pressures, and are inert. PFCs do not react with living tissues due to their carbon-fluorine bonds, which cannot be metabolized in vivo, and they have low intermolecular forces, and hence, the surface tension of the liquid form of PFCs is extremely low. Most PFCs have a surface tension of 14–18 dyne/cm [9]. As gases, PFCs show some toxicity, while in a liquid form they are relatively safe [10]. Clearance of PFC agents from the body generally occurs via the mononuclear phagocyte system (MPS) uptake (phagocytic cells primarily in lymph nodes, spleen, and liver) and finally lung exhalation. Some PFCs can also bind and dissolve oxygen. This led to their early use as blood substitutes, although the idea has been commercially abandoned. PFCs are still used clinically, for example for partial liquid ventilation [LiquiVent, Alliance Pharmaceutical Corporation], eye surgery [Perfluoron™, Alcon® Inc., USA], and as ultrasound contrast agents as gas bubbles [Sonovue®, Bracco International B.V.] (Fig. 2a).
PFCs have now found their use as imaging labels for ultrasonography, computed tomography, and 19F MRI. Their use in the latter imaging method is especially beneficial, as PFCs have a high payload of fluorine atoms, which makes 19F MRI a promising modality for in vivo quantitative imaging, including in vivo cell tracking. Here, liquid PFCs are more suitable, as they result in the most favorable imaging characteristics.
For imaging purposes, PFCs offer a high 19F density per molecule, and thus high sensitivity, provided that multiple fluorine resonances do not occur. To avoid such chemical shift artifacts, PFCs such as ring ethers or longer linear ether chains are frequently used [5, 11]. The most frequently used 19F MRI labels consist of perfluorooctyl bromide (PFOB), perfluoro-15-crown-5-ether (PFCE), and a linear PFPE polymer mixture, which is commercialized as Cell Sense (Celsense Inc., Pittsburgh PA, USA). Characteristics of examples of these PFCs are shown in Table 1, while Fig. 2b shows the structure of PFCE, PFOB, and PFPE.
PFCs have a unique and sometimes undesirable characteristic, in that they are fluorophilic, i.e., simultaneously lipophobic and hydrophobic (Fig. 2b). Consequently, PFCs separate when placed in an aqueous environment and are immiscible in cell membranes. Because of this, they require emulsification, to form nanoemulsions, or entrapment into particles to achieve stability in biological environments. In such forms, PFCs can also be used to label cells for in vivo cell tracking.
3 19F MRI Labels
The ideal 19F label needs to have certain characteristics, described in more detail elsewhere [2]. Briefly, such an agent has to be biologically inert and chemically stable. Fluorinated compounds should be nontoxic for the host and have minimal impact on labeled cell function. The label needs to be suitable for cell uptake, with smaller droplets or particles for intracellular labeling and potentially larger ones for blood pool imaging. What is more, cells need to take up sufficient amounts of the label in order to be detected (ranging from 0.5 to 30 × 1012 19F atoms/cell) [5]. The “sufficient amount” is based on the number of cells per voxel and T1 and T2 characteristics of the compound. Last, but not least, the 19F compounds must have beneficial relaxation parameters, with a short T1 and a long T2 [2]. Typical labels are composed of a fluorinated molecule and a coating or surfactant which stabilizes the fluorocarbon to make it more suitable for cell labeling and cell uptake (Fig. 3).
In general, high signal density per molecule is necessary. Therefore, most labels consist of fluorocarbon or even liquid PFCs such as perfluoropolyethers (PFPE), typically administered as nanoemulsions with droplet sizes around 100–300 nm. Due to their poor miscibility, PFCs need to be “packaged” to stabilize them in aqueous biological environments. These packaging techniques are discussed in the following section.
3.1 Label Formulation: “PFC Packaging ”
Cell tracking applications require PFCs to be formulated into a biocompatible label. There are several methods to formulate fluorinated labels. The route of synthesis depends on the type of label, its size, properties, and addition of extra molecules, e.g., fluorescent dyes. Emulsions are prepared via emulsification processes using, e.g., sonication or microfluidization. Emulsions should have a small, uniform droplet size, ideally smaller than 200 nm, as larger droplets may affect cell activation phenotype post-labeling [11]. However, the poor affinity between the PFC, surfactant, and aqueous continuous phase can limit emulsion stability. Furthermore, it can be difficult to add additional agents such as fluorescent dyes, drugs, or antibodies without changing the emulsion properties. Furthermore, the addition of extra moieties to an emulsion can result in separation of those moieties from PFC in the cell or in vivo, with no assurance of their localization. Recently, nanoparticles have received a lot of interest [5, 12], due to their enhanced stability. A key advantage of using particles is that the components of the particles can be modified without altering the formulation protocol.
3.2 Emulsions
Emulsions are the simple product of vigorously mixing oil and water. More specifically, an emulsion is a suspension of two immiscible liquids. In the literature, emulsion droplets are frequently referred to as “particles” but to avoid confusion, here particles are defined as solids which can be isolated from and added back to the continuous phase (water or buffer) without undergoing changes other than hydration, with the particles being able to be stored as powder. Emulsion droplets cannot be isolated in such fashion without losing stability.
Emulsions are the most commonly used cell labels due to their high content of PFCs per droplet and simplicity of production. Emulsions consist of an immiscible compound that is surrounded by a surfactant. The role of the surfactant is to stabilize the formed droplets in the continuous phase (water) and delay the PFC from settling out and coalescing to form a separate layer. PFC emulsions for MRI generally exhibit poor stability due to the fact that the surfactant used cannot be miscible with both the PFC and water, unless it is a fluorinated surfactant. Fluorinated surfactants are avoided, due to the potential for toxicity and the chemical shift artifacts that can result from the added fluorine. PFC emulsions are described in more detail elsewhere [13].
Recently a new compound called PERFECTA has been developed as a 19F MRI tracer. PERFECTA is a superfluorinated molecular probe suitable for in vivo cell tracking. It has high detection sensitivity, a single, sharp resonance peak, and attractive T1 and T2 values [14]. PERFECTA is not fully fluorinated, but has a hydrocarbon polar core and four ether bonds, which might undergo enzymatic degradation in vivo. Most other recent studies have focused on conventional, existing PFCs [12, 15–17]. Figure 3 shows a representation of an emulsion droplet, a nanoparticle, and a large fluorinated molecule.
3.3 Micelles
Micelles are lipid-based compounds composed of amphiphilic molecules that undergo spontaneous self-assembly in an aqueous solution. This spontaneous self-assembly is due to the amphipathic nature of the molecule. To form a micelle, the amphiphilic molecules arrange in a way where the hydrophobic groups create a core, while the hydrophilic groups are on the outside and have contact with water [18]. The size of micelles ranges from 2 to 20 nm, and it depends on their composition, modifications, and concentration. There have been several studies incorporating a hydrophilic Gd(III) chelate into micelles for in vivo imaging [19–21] to enhance the T1 MRI contrast. Micelles can be further modified with groups that bind to specific targets.
3.4 Dendrimers
Dendrimers are nanoscale macromolecules that have well-defined polymeric chains which branch off from a central core. They can be functionalized with polyfluorinated groups and targeting moieties. Dendrimers modified with Gd(III) chelate show increase in rotational correlation times which leads to strong enhancement in T1 relaxation rates when compared to lower molecular weight chelates [18]. Dendrimers typically present prolonged retention times within the vascular system in comparison to lower molecular weight chelates, which usually undergo a fast renal clearance.
Dendrimers are very appealing in 19F MRI label design due to large number of surface functional groups which can be reacted with polyfluorinated precursors, leading to materials with potentially high concentrations of fluorine nuclei [18]. However, it is possible that dendrimers may be metabolized in vivo leading to potentially toxic compounds. In general, less is known about these extremely large molecules and their in vivo behavior.
3.5 PFC Nanoparticles
Particles are an attractive alternative for 19F MRI compared to conventional liquid emulsion droplets, as they are more stable and can be frozen as a dry powder for easy storage and transport [5]. PFC nanoparticles typically consist of a PFC entrapped in a solid polymer. We previously reported on stable encapsulation of PFC in poly(d,l-lactide-co-glycolide acid) (PLGA) particles [22]. The PFC-PLGA particles were prepared using single-emulsion solvent-evaporation method. In this method, the polymer is dissolved in an organic solvent, and the PFCE is added. Next, this organic phase is added to an aqueous solution containing surfactant under sonication. The role of surfactant is to stabilize the cells and prevent Ostwald ripening (which is very common in emulsions, including PFC emulsions) [23]. Sonication is then followed by solvent evaporation, and washing and freeze-drying of particles. After the last step, particles can be stored in a powder form for extended periods of time. PLGA-PFC particles can be easily modified with targeting ligands, and fluorescent dyes, and they can also be used to encapsulate drugs.
There are several methods to characterize PFC nanoparticles, for example dynamic light scattering, electron microscopy, and nuclear magnetic resonance (NMR) . The first two methods are used to study diameter, while 19F NMR is used to measure fluorine content. PFC particles prepared with solvent evaporation method typically have a diameter of 200 nm, comparable to many PFC emulsion droplets.
4 Cell Labeling
Most of the studies performed thus far in this field have used naturally phagocytic cells, such as macrophages or DCs. These types of cells readily phagocytose label droplets or particles, generally resulting in labeling in the order of 1010–1013 fluorine atoms per cell (see Table 1).
A general cell labeling protocol is shown in Fig. 4. Key labeling steps include the length of time the cells are incubated with the label, the concentration of the label, and removal of excess label. Label uptake can be encouraged when necessary through the use of positive changes on the labels, such as through transfection agents [24]. It is important to show that the label is incorporated in a stable manner within the cell, and will remain within the relevant cell in vivo. In addition, it needs to be ensured that any excess label is removed through careful washing steps before transfer to the subject.
It is also necessary to balance the uptake of label with any effects on cell functionality and cytotoxicity. In particular, it is vital to assess any effect of the label on cell migration and other functions that are necessary in vivo. It has been shown that iron oxide labeling can alter cell migration in neural stem cells [25], although another study that exhaustively compared various labels including iron oxide and 19F did not find any effect in mesenchymal stem cells [26]. Thus, the effect of labeling appears to be cell dependent and label dependent at the very least. Furthermore, with some fluorine labels, cell migration is known to be unaffected, and 19F MRI has in fact been suggested as a cell migration assay for larger cell numbers [27]. However, one cannot assume that any particular label will not affect migration, or any particular function, in a different cell type, i.e., each cell type-label pair needs to be individually optimized and thoroughly characterized.
In all cases, quantification of cell numbers is much more accurate when cells are labeled ex vivo, as the average 19F content per cell can be readily determined. When the label is injected systemically [28] in vivo, and subsequently taken up by target cells (typically macrophages), quantification becomes more complex, as the label uptake per cell cannot be determined. Even with ex vivo-labeled cells, the label can be lost or transferred to other cell types, particularly macrophages present within the surrounding host tissue. For example, labeled mesenchymal stem cells lost their 19F agent to bystander macrophages by 17 days after transfer [29]. Thus, the signal detected could be falsely interpreted at later time points. Such label transfer may vary depending on cell type, label type, transfer site, division status of the cells, and various other factors. Similar results were also obtained in another study [30], where transgenic neural stem cells expressing a bioluminescence marker were also labeled with a fluorinated agent. Here, the 19F signal was retained for at least several days after the bioluminescence signal was lost, and indicator of cell death (Fig. 5). This slow loss of 19F signal even after cell death could be a result of various factors including the particular properties of the label or cell, or simply slow clearance from the brain. Regardless, these studies highlight that the interpretation of cell tracking can become more complex after its initial stages.
The fate of the agent, both in cells and in vivo, is an important consideration, particularly in terms of any toxicity and the clearance rate and route. This may be less of an issue if cells are prelabeled ex vivo before injection to the subject, as then only very small amounts of PFCs are administered. However, in cases where cells are labeled in vivo, after systemic injection of the agent, retention and clearance are important considerations [31] (Fig. 6). In one study, it was found that the biological half-life of different PFCs administered as emulsions varied from 9 days to over 250 days. However, the influence of the type of label, surfactant used, site of injection, and other factors is not clear.
5 Recent Developments
5.1 Multicolor 19F MRI
The broad chemical shift of 19F allows the possibility of imaging well-separated resonances. Multiple resonances are most often a drawback, as they represent “lost” 19Fs that do not contribute to the signal, or that create artifacts making the image “fuzzy” (Fig. 7). However, in some cases this drawback can be harnessed to image multiple cell lines at different resonance frequencies. Recently, this has been applied to different therapeutic cell subsets, which were labeled with different PFCs (PFO and PFCE, respectively) [12] (Fig. 8). A standard gradient-echo sequence was used for imaging, where the excitation peak was sufficiently broad so as to excite both the main resonance of the PFO and the single resonance of the PFCE. Both were detected simultaneously, but due to the known bandwidth per voxel, the signals could be separated. The technique clearly has limitations, for example, in applications where the cell distribution is very complex. Still, it allows imaging of two cell populations simultaneously. Such work has also been carried out with stem cells, using spectroscopic imaging [32].
5.2 Multimodal Imaging
No single imaging modality is perfect and able to provide all the necessary answers with certainty. In fact, nowadays the majority of 19F cell tracking imaging studies use multimodal imaging, most often combining MRI with fluorescence, either in vivo or ex vivo using histopathology. The advantages of multimodal cell tracking include verification of data obtained using a new imaging agent or technique with an established one, and the ability to gather complementary information from a single experiment.
6 Conclusions and Future Outlook
19F MRI for cell tracking has recently been demonstrated in the clinic [15]; thus its clinical applicability is no longer in dispute. There is still no consensus on which PFC, if any, is the best for in vivo application, particularly in terms of balancing imaging favorability with retention times, and new and more “ideal” compounds are continually being generated. Furthermore, the relatively long imaging times necessary and limited availability of suitable hardware to do 19F MRI are still a hindrance for the broad application of 19F MRI. Regardless, given all the advantages and unique possibilities outlined briefly in this chapter, the future of “hot-spot” imaging, particularly for cell tracking, is getting hotter.
References
de Vries IJ et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005;23(11):1407–13.
Srinivas M, Heerschap A, Ahrens ET, Figdor CG, de Vries IJ. 19F MRI for quantitative in vivo cell tracking. Trends Biotechnol. 2010;28.
Zhong J, Narsinh K, Morel PA, Xu H, Ahrens ET. In vivo quantification of inflammation in experimental autoimmune encephalomyelitis rats using fluorine-19 magnetic resonance imaging reveals immune cell recruitment outside the nervous system. PLoS One. 2015;10(10).
Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol. 2005;23.
Srinivas M, Boehm-Sturm P, Figdor CG, de Vries IJ, Hoehn M. Labelling cells for in vivo cell tracking using 19F MRI. Biomaterials. 2012;33.
Diou O, Tsapis N, Giraudeau C, Valette J, Gueutin C, Bourasset F, et al. Long-circulating perfluorooctyl bromide nanocapsules for tumor imaging by 19FMRI. Biomaterials. 2012;33.
Chubarov AS, Zakharova OD, Koval OA, Romaschenko AV, Akulov AE, Zavjalov EL, et al. Design of protein homocystamides with enhanced tumor uptake properties for 19F magnetic resonance imaging. Bioorg Med Chem. 2015;23(21).
Yuan Y, Ge S, Sun H, Dong X, Zhao H, An L, et al. Intracellular self-assembly and disassembly of 19F nanoparticles confer respective “Off” and “On” 19F NMR/MRI signals for Legumain activity detection in zebrafish. ACS Nano. 2015;9(5).
Sarkar S, Paswan A, Prakas S. Liquid ventilation. Anesth Essays Res. 2014;8(3).
Cosco D, Fattal E, Fresta M, Tsapis N. Perfluorocarbon-loaded micro and nanosystems for medical imaging: A state of the art. J Fluorine Chem. 2015;171.
Ahrens ET, Zhong J. In vivo MRI cell tracking using perfluorocarbon probes and fluorine-19 detection. NMR Biomed. 2013;26(7).
Srinivas M, Tel J, Schreibelt G, Bonetto F, Cruz LJ, Amiri H, et al. PLGA-encapsulated perfluorocarbon nanoparticles for simultaneous visualization of distinct cell populations by 19F MRI. Nanomedicine. 2015;10(15).
Janjic JM, Ahrens ET. Fluorine-containing nanoemulsions for MRI cell tracking. Adv Rev. 2009;1(5).
Ilaria Tirotta, et al. A superfluorinated molecular probe for highly sensitive in vivo19F-MRI. J Am Chem Soc. 2014;136.
Ahrens ET, Helfer BM, O’Hanlon CF, Schirda C. Clinical cell therapy imaging using a perfluorocarbon tracer and fluorine-19 MRI. Magn Reson Med. 2014;72(6).
Kadayakkara DK, Damodaran K, Hitchens TK, Bulte JW, Ahrens ET. (19)F spin-lattice relaxation of perfluoropolyethers: Dependence on temperature and magnetic field strength (7.0-14.1T). J Magn Reson. 2014;242.
de Vries A, Moonen R, Yildirim M, Langereis S, Lamerichs R, Pikkemaat JA, et al. Relaxometric studies of gadolinium-functionalized perfluorocarbon nanoparticles for MR imaging. Contrast Media Mol Imaging. 2014;9(1).
Knight JC, Edwards PG, Paisey SJ. Fluorinated contrast agents for magnetic resonance imaging; a review of recent developments. RSC Adv. 2011;1.
Zhang G, Zhang R, Wen X, Li L, Li C. Micelles based on biodegradable poly(L-glutamic acid)-b-polylactide with paramagnetic Gd ions chelated to the shell layer as a potential nanoscale MRI-visible delivery system. Biomacromolecules. 2008;9(1).
Grogna M, Cloots R, Luxen A, Jérôme C, Passirani C, Lautram N, et al. Polymer micelles decorated by gadolinium complexes as MRI blood contrast agents: design, synthesis and properties. Polymer Chem. 2010;1.
Mouffouk F, Simão T, Dornelles DF, Lopes AD, Sau P, Martins J, et al. Self-assembled polymeric nanoparticles as new, smart contrast agents for cancer early detection using magnetic resonance imaging. Int J Nanomed. 2015;10.
Srinivas M, Cruz LJ, Bonetto F, Heerschap A, Figdor CG, de Vries IJ. Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging. Biomaterials. 2010;31(27).
Patel SK, Williams J, Janjic JM. Cell Labeling for 19F MRI: new and improved approach to perfluorocarbon nanoemulsion design. Biosensors. 2013;3(3).
Srinivas M, Turner MS, Janjic JM, Morel PA, Laidlaw DH, Ahrens ET. In vivo cytometry of antigen-specific t cells using 19F MRI. Magn Reson Med. 2009;62(3).
Cromer Berman SM, Kshitiz, Wang CJ, Orukari I, Levchenko A, Bulte JW, Walczak P. Cell motility of neural stem cells is reduced after SPIO-labeling, which is mitigated after exocytosis. Magn Reson Med. 2013;69(1).
Muhammad G, Jablonska A, Rose L, Walczak P, Janowski M. Effect of MRI tags: SPIO nanoparticles and 19F nanoemulsion on various populations of mouse mesenchymal stem cells. Acta Neurobiol Exp. 2015;75(2).
Bonetto F, Srinivas M, Weigelin B, Cruz LJ, Heerschap A, Friedl P, et al. A large-scale (19)F MRI-based cell migration assay to optimize cell therapy. NMR Biomed. 2012;25(9).
Bönner F, Merx MW, Klingel K, Begovatz P, Flögel U, Sager M, et al. Monocyte imaging after myocardial infarction with 19F MRI at 3 T: a pilot study in explanted porcine hearts. Eur Heart J Cardiovasc Imaging. 2015;16(6).
Gaudet JM, Ribot EJ, Chen Y, Gilbert KM, Foster PJ. Tracking the fate of stem cell implants with fluorine-19 MRI. PLoS One. 2015;10(3).
Boehm-Sturm P, Aswendt M, Minassian A, Michalk S, Mengler L, Adamczak J, et al. A multi-modality platform to image stem cell graft survival in the naïve and stroke-damaged mouse brain. Biomaterials. 2014;35(7).
Jacoby C, Temme S, Mayenfels F, Benoit N, Krafft MP, Schubert R, et al. Probing different perfluorocarbons for in vivo inflammation imaging by 19F MRI: image reconstruction, biological half-lives and sensitivity. NMR Biomed. 2013;27(3).
Partlow KC, Chen J, Brant JA, Neubauer AM, Meyerrose TE, Creer MH, et al. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J. 2007;21(8).
Mizukami S, Takikawa R, Sugihara F, Hori Y, Tochio H, Wälchli M, et al. Paramagnetic relaxation-based 19f MRI probe to detect protease activity. J Am Chem Soc. 2008;130(3).
Boehm-Sturm P, Mengler L, Wecker S, Hoehn M, Kallur T. In vivo tracking of human neural stem cells with 19F magnetic resonance imaging. PLoS One. 2011;6(12).
Liu L, Ye Q, Wu Y, Hsieh WY, Chen CL, Shen HH, et al. Tracking T-cells in vivo with a new nano-sized MRI contrast agent. Nanomedicine. 2012;8(8).
Waiczies H, Lepore S, Janitzek N, Hagen U, Seifert F, Ittermann B, et al. Perfluorocarbon particle size influences magnetic resonance signal and immunological properties of dendritic cells. PLoS One. 2011;6(7).
Thorek DLJ, Tsourkas A. Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials. 2009;29(26).
Jain AK, Das M, Swarnakar NK, Jain S. Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Critic Rev Therapeut Drug Carrier Syst. 2011;28(1).
Luo R, Neu B, Venkatraman SS. Surface functionalization of nanoparticles to control cell interactions and drug release. Small. 2012;8(16).
Flaim SF. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif Cells Blood Subst Biotechnol. 1994;22(4).
Du W, Xu Z, Nyström AM, Zhang K, Leonard JR, Wooley KL. 19F- and fluorescently labeled micelles as nanoscopic assemblies for chemotherapeutic delivery. Bioconjugate Chem. 2008;19(12).
Hitchens TK, Ye Q, Eytan DF, Janjic JM, Ahrens ET, Ho C. 19F MRI detection of acute allograft rejection with in vivo perfluorocarbon labeling of immune cells. Magn Reson Med. 2011;65(4).
Ruiz-Cabello J, Barnett BP, Bottomley PA, Bulte JW. Fluorine (19F) MRS and MRI in biomedicine. NMR Biomed. 2011;24(2).
Maki J, Masuda C, Morikawa S, Morita M, Inubushi T, Matsusue Y, et al. The MR tracking of transplanted ATDC5 cells using fluorinated poly-l-lysine-CF3. Biomaterials. 2007;28(3).
Masuda C, Maki Z, Morikawa S, Morita M, Inubushi T, Matsusue Y, et al. MR tracking of transplanted glial cells using poly-l-lysine-CF3. Neurosci Res. 2006;56(2).
Bommerich U, Trantzschel T, Mulla-Osman S, Buntkowsky G, Bargon J, Bernarding J. Hyperpolarized 19F-MRI: parahydrogen-induced polarization and field variation enable 19F-MRI at low spin density. Phys Chem Chem Phys. 2010;12(35).
Acknowledgment
This work was supported by the European Research Council (ERC) Starting Grant (CoNQUeST Grant no. 336454) to MS.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Swider, E., Srinivas, M. (2017). Spinning to a Different Beat: 19F Agents for “Hot-Spot” Cellular MR Imaging. In: Bulte, J., Modo, M. (eds) Design and Applications of Nanoparticles in Biomedical Imaging. Springer, Cham. https://doi.org/10.1007/978-3-319-42169-8_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-42169-8_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42167-4
Online ISBN: 978-3-319-42169-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)